Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Foglesong, US

Robert E. Foglesong, Houston, TX US

Patent application numberDescriptionPublished
20100074692Open-Sea Berth LNG Import Terminal - Methods and systems for receiving liquefied natural gas (LNG) and delivering vaporized natural gas to a pipeline in fluid communication with onshore equipment and methods for importing LNG. In one embodiment, an open-sea berth import terminal includes a platform, which is fixed to the sea floor and includes two or more sets of berthing structures. LNG carriers berth at the open-sea berth import terminal to transfer LNG to a storage vessel moored at one of the berthing structures. LNG vaporization facilities, either on the storage vessel or the platform, vaporize the LNG prior to delivery to the pipeline. The storage vessel may include a barge or another LNG carrier. In other embodiments, the open-sea berth import terminal may have no storage facilities, but two LNG carriers may berth at the berthing structures to concurrently perform offloading operations, with one transferring LNG and the other performing other offloading operations to enhance operations.03-25-2010

Robert J. Foglesong, Durham, NC US

Patent application numberDescriptionPublished
20090099248INHIBITORS OF D-AMINO ACID OXIDASE - The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.04-16-2009
20100022612FUSED HETEROCYCLES - This invention provides fused heterocycles having the formula:01-28-2010
20100029737INHIBITORS OF D-AMINO ACID OXIDASE - The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.02-04-2010
20100029741FUSED HETEROCYCLES - This invention provides methods of improving cognitive function by administering to a subject a therapeutically effective amount of a fused heterocycle having the formula:02-04-2010
20100120740PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE - The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.05-13-2010
20110034434PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE - The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.02-10-2011

Patent applications by Robert J. Foglesong, Durham, NC US

Robert James Foglesong, Durham, NC US

Patent application numberDescriptionPublished
20080234292Peptidase Inhibitors - The present invention relates to a series of novel compounds having the formula (I) wherein: X is NR09-25-2008